FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2609128313> ?p ?o ?g. }

• W2609128313 endingPage "229" @default.
• W2609128313 startingPage "215" @default.
• W2609128313 abstract "Objectives: The indication for screening for valvular heart disease in patients taking cabergoline is based on evidence from patients with Parkinson’s disease on high-dose medication. However, current patients take much lower doses for indications such as hyperprolactinaemia disorders. Contemporary guidelines for echocardiogram monitoring in patients taking cabergoline are conflicting. This study aimed to review current clinical practice in our area regarding echocardiographic screening and to review the literature examining the evidence of valvular heart disease in patients taking lower dose cabergoline. Methods: This was a retrospective study of all patients with hyperprolactinaemia disorders prescribed cabergoline in a single UK NHS health board between January 2014 and July 2015. The proportion of patients receiving baseline and follow-up echocardiograms was recorded. A review of the published literature was carried out using the databases EMBASE and Medline to examine the current evidence for the effect cabergoline has on cardiac valves in patients treated for hyperprolactinaemia disorders. Results: The mean age was 51.7 ± 16.5 years with a 64.4% female predominance. The mean duration of therapy was 5.9 years ± 4.1 years. Of the total cohort ( n = 45), two (4.4%) patients had an initial baseline echocardiogram and five (13.2%) had follow-up echocardiograms every 24 months. Of the 25 articles identified, 12 showed no clinically significant evidence of valvular dysfunction in the cabergoline group groups. Of the remaining 13 articles, evidence for valvular changes was confined to high cumulative dose cabergoline patients and there was only one confirmed case of ‘cabergoline associated valvulopathy’ described. Conclusions: Clinically significant valvular dysfunction is uncommon and generally only reported in high cumulative dose treatment groups. We propose that clearer national guidelines are required and that echocardiogram screening be reserved for patients who are high risk, are taking a high weekly dose (≥2 mg cabergoline weekly) or high cumulative dose." @default.
• W2609128313 created "2017-05-05" @default.
• W2609128313 creator A5030517103 @default.
• W2609128313 creator A5047624828 @default.
• W2609128313 creator A5052556297 @default.
• W2609128313 creator A5053435842 @default.
• W2609128313 creator A5064130539 @default.
• W2609128313 creator A5083702379 @default.
• W2609128313 date "2017-04-25" @default.
• W2609128313 modified "2023-09-28" @default.
• W2609128313 title "Screening for valve disease in patients with hyperprolactinaemia disorders prescribed cabergoline: a service evaluation and literature review" @default.
• W2609128313 cites W1497341086 @default.
• W2609128313 cites W1569729925 @default.
• W2609128313 cites W1590754848 @default.
• W2609128313 cites W1984499153 @default.
• W2609128313 cites W1993320494 @default.
• W2609128313 cites W1998396979 @default.
• W2609128313 cites W2007440241 @default.
• W2609128313 cites W2019055295 @default.
• W2609128313 cites W2023461773 @default.
• W2609128313 cites W2025518398 @default.
• W2609128313 cites W2029179034 @default.
• W2609128313 cites W2034841744 @default.
• W2609128313 cites W2055254907 @default.
• W2609128313 cites W2069875099 @default.
• W2609128313 cites W2079846716 @default.
• W2609128313 cites W2085963717 @default.
• W2609128313 cites W2095822722 @default.
• W2609128313 cites W2096923719 @default.
• W2609128313 cites W2100969268 @default.
• W2609128313 cites W2101764902 @default.
• W2609128313 cites W2112309011 @default.
• W2609128313 cites W2115280831 @default.
• W2609128313 cites W2123915391 @default.
• W2609128313 cites W2145655269 @default.
• W2609128313 cites W2156868015 @default.
• W2609128313 cites W2159178428 @default.
• W2609128313 cites W2265796669 @default.
• W2609128313 cites W2291029454 @default.
• W2609128313 cites W2346633334 @default.
• W2609128313 cites W2512156014 @default.
• W2609128313 cites W2528019457 @default.
• W2609128313 cites W4239471525 @default.
• W2609128313 doi "https://doi.org/10.1177/2042098617703647" @default.
• W2609128313 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5564889" @default.
• W2609128313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28845230" @default.
• W2609128313 hasPublicationYear "2017" @default.
• W2609128313 type Work @default.
• W2609128313 sameAs 2609128313 @default.
• W2609128313 citedByCount "8" @default.
• W2609128313 countsByYear W26091283132018 @default.
• W2609128313 countsByYear W26091283132019 @default.
• W2609128313 countsByYear W26091283132020 @default.
• W2609128313 countsByYear W26091283132022 @default.
• W2609128313 crossrefType "journal-article" @default.
• W2609128313 hasAuthorship W2609128313A5030517103 @default.
• W2609128313 hasAuthorship W2609128313A5047624828 @default.
• W2609128313 hasAuthorship W2609128313A5052556297 @default.
• W2609128313 hasAuthorship W2609128313A5053435842 @default.
• W2609128313 hasAuthorship W2609128313A5064130539 @default.
• W2609128313 hasAuthorship W2609128313A5083702379 @default.
• W2609128313 hasBestOaLocation W26091283131 @default.
• W2609128313 hasConcept C126322002 @default.
• W2609128313 hasConcept C167135981 @default.
• W2609128313 hasConcept C187212893 @default.
• W2609128313 hasConcept C2779064019 @default.
• W2609128313 hasConcept C2779134260 @default.
• W2609128313 hasConcept C2779736815 @default.
• W2609128313 hasConcept C2779832395 @default.
• W2609128313 hasConcept C2781401123 @default.
• W2609128313 hasConcept C71315377 @default.
• W2609128313 hasConcept C71924100 @default.
• W2609128313 hasConcept C72563966 @default.
• W2609128313 hasConceptScore W2609128313C126322002 @default.
• W2609128313 hasConceptScore W2609128313C167135981 @default.
• W2609128313 hasConceptScore W2609128313C187212893 @default.
• W2609128313 hasConceptScore W2609128313C2779064019 @default.
• W2609128313 hasConceptScore W2609128313C2779134260 @default.
• W2609128313 hasConceptScore W2609128313C2779736815 @default.
• W2609128313 hasConceptScore W2609128313C2779832395 @default.
• W2609128313 hasConceptScore W2609128313C2781401123 @default.
• W2609128313 hasConceptScore W2609128313C71315377 @default.
• W2609128313 hasConceptScore W2609128313C71924100 @default.
• W2609128313 hasConceptScore W2609128313C72563966 @default.
• W2609128313 hasIssue "7" @default.
• W2609128313 hasLocation W26091283131 @default.
• W2609128313 hasLocation W26091283132 @default.
• W2609128313 hasLocation W26091283133 @default.
• W2609128313 hasLocation W26091283134 @default.
• W2609128313 hasOpenAccess W2609128313 @default.
• W2609128313 hasPrimaryLocation W26091283131 @default.
• W2609128313 hasRelatedWork W1497341086 @default.
• W2609128313 hasRelatedWork W1569729925 @default.
• W2609128313 hasRelatedWork W1982209155 @default.
• W2609128313 hasRelatedWork W1993320494 @default.
• W2609128313 hasRelatedWork W2096923719 @default.
• W2609128313 hasRelatedWork W2763326319 @default.
• W2609128313 hasRelatedWork W2806212162 @default.

• next